This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

VIVES Stock Overview

Develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. More details

VIVES fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Has less than 1 year of cash runway

Earnings have declined by 8.5% per year over past 5 years

Makes less than USD$1m in revenue (SEK7M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Vivesto AB Competitors

BSF Enterprise

LSE:BSFA

UK£2.5m

Theracryf

AIM:TCF

UK£2.3m

Arecor Therapeutics

AIM:AREC

UK£26.2m

ProBiotix Health

OFEX:PBX

UK£9.1m

Price History & Performance

Summary of share price highs, lows and changes for Vivesto
Historical stock prices
Current Share Price	SEK 0.28
52 Week High	SEK 0
52 Week Low	SEK 0
Beta	0.63
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	VIVES	GB Biotechs	GB Market
7D	n/a	-4.2%	-2.6%
1Y	n/a	-24.5%	2.4%

Return vs Industry: Insufficient data to determine how VIVES performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how VIVES performed against the UK Market.

Price Volatility

Is VIVES's price volatile compared to industry and market?
VIVES volatility
VIVES Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: VIVES has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine VIVES's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1988	6	Erik Kinnman	www.vivesto.com

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.

Vivesto AB Fundamentals Summary

How do Vivesto's earnings and revenue compare to its market cap?
VIVES fundamental statistics
Market cap	SEK 145.27m
Earnings (TTM)	-SEK 116.77m
Revenue (TTM)	SEK 6.61m

22.0x

P/S Ratio

-1.2x

P/E Ratio

Is VIVES overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VIVES income statement (TTM)
Revenue	SEK 6.61m
Cost of Revenue	SEK 0
Gross Profit	SEK 6.61m
Other Expenses	SEK 123.38m
Earnings	-SEK 116.77m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 22, 2024

Earnings per share (EPS)	-0.22
Gross Margin	100.00%
Net Profit Margin	-1,766.05%
Debt/Equity Ratio	0%

How did VIVES perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/07/07 00:39
End of Day Share Price	2024/07/01 00:00
Earnings	2024/03/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vivesto AB is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Camilla Oxhamre	Carnegie Investment Bank AB
Susie Jana	Edison Investment Research
Sean Conroy	Edison Investment Research